The registration, which was filed under InB: Hauser Pharmaceutical Services, will now allow the firm to immediately manufacture schedule II-V compounds.
With the new DEA registration status CHO can manufacture controlled substances and provide additional capacity when needed to its existing controlled substance manufacturing capacities at its Grafton, Wisconsin facility in the US.
Cedarburg Hauser Pharmaceuticals vice president and general manager, Joe Guiles said the GMP manufacturing and analytical method development expertise of firm’s Denver facility may now be extended to DEA scheduled compounds.
"This further emphasizes these competencies, and represents an opportunity to expand our customer base and serve the needs of our existing customers," Guiles added.